LB Pharmaceuticals Inc Common Stock(LBRX)

Biotechnology · New York, NY

$34.16-0.46 (-1.34%)

Delayed quote: Oct 6, 2026, 1:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T17:02:59.616Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:02:59.616Z.

Quote observation: 2026-10-06T17:00:54.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 979,525,608
Total debt · period ending 2026-06-30: 5,217,000
Cash · period ending 2026-06-30: 283,111,000
TTM operating income · period ending 2026-06-30: -95,135,000

FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

LBRX EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

LBRX Competitors' EV/EBIT Ratio

LBRX

LB Pharmaceuticals Inc Common Stock

Current

Market Cap

$979.53M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGTX

MeiraGTx Holdings plc

vs LBRX

Market Cap

$979.81M

EV/EBIT Ratio

5.16x

TTM Avg

6.47x

3Y Avg

6.47x

5Y Avg

6.47x

PCRX

Pacira BioSciences, Inc.

vs LBRX

Market Cap

$983.38M

EV/EBIT Ratio

64.50x

TTM Avg

51.40x

3Y Avg

38.19x

5Y Avg

39.85x

AKTS

Aktis Oncology, Inc.

vs LBRX

Market Cap

$966.65M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRCT

PROCEPT BioRobotics Corporation

vs LBRX

Market Cap

$991.20M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LTGO

Latigo Biotherapeutics Inc.

vs LBRX

Market Cap

$1.00B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SVRA

Savara Inc.

vs LBRX

Market Cap

$952.91M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPTX

Seaport Therapeutics, Inc. Common Stock

vs LBRX

Market Cap

$950.17M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KURA

Kura Oncology, Inc.

vs LBRX

Market Cap

$950.77M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MLTX

MoonLake Immunotherapeutics

vs LBRX

Market Cap

$939.15M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
LB Pharmaceuticals Inc Common Stock (LBRX)	$979.53M	N/A	N/A	N/A	N/A
MeiraGTx Holdings plc (MGTX)vs ›	$979.81M	5.16x	6.47x	6.47x	6.47x
Pacira BioSciences, Inc. (PCRX)vs ›	$983.38M	64.50x	51.40x	38.19x	39.85x
Aktis Oncology, Inc. (AKTS)vs ›	$966.65M	N/A	N/A	N/A	N/A
PROCEPT BioRobotics Corporation (PRCT)vs ›	$991.20M	N/A	N/A	N/A	N/A
Latigo Biotherapeutics Inc. (LTGO)vs ›	$1.00B	N/A	N/A	N/A	N/A
Savara Inc. (SVRA)vs ›	$952.91M	N/A	N/A	N/A	N/A
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$950.17M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$950.77M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$939.15M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

LBRX EV/EBIT Ratio Metrics

LBRX Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics